HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Related articles in Proceedings of the American Thoracic Society Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, D. L. Articles by Dehdashti, F. Search for Related Content PubMed PubMed Citation Articles by Chen, D. L. Articles by Dehdashti, F.

Advances in Positron Emission Tomographic Imaging of Lung Cancer

Division of Nuclear Medicine, Edward Mallinckrodt Institute of Radiology; and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri

Correspondence and requests for reprints should be addressed to Delphine L. Chen, M.D., Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Campus Box 8223, 510 S. Kingshighway Boulevard, St. Louis, MO 63110. E-mail: chend{at}mir.wustl.edu

ABSTRACT

Positron emission tomography (PET) with [¹⁸F]fluorodeoxyglucose (FDG) has been established as a useful tool in the management of patients with non-small cell lung cancer and promises to be as valuable in the clinical management of other cancers. PET imaging with FDG allows the assessment of tumor glucose metabolism in vivo; however, a number of other PET tracers are being used in oncologic research to assess changes in other cellular processes associated with malignant transformation of the cell. [¹¹C]-Labeled methionine and choline are being used to assess changes in cell membrane synthesis; however, small studies have not shown the added information from these tracers to be clinically useful. DNA synthesis can be assessed by measuring the uptake of the thymidine analog 3'-deoxy-3'-[¹⁸F]fluorothymidine, which may be more specific for evaluating malignancy without the problem of false-positive results from inflammatory lesions, as seen with FDG. Tumor hypoxia imaging with copper-labeled diacetyl-bis(N(4)-methylthiosemicarbazone) or [¹⁸F]fluoromisonidazole may provide a better method of predicting which tumors will respond best to conventional therapy. The role of PET will continue to evolve with further clinical studies using these and other new tracers.

Key Words: FDG • cell proliferation • cell hypoxia

Related articles in Proceedings of the American Thoracic Society:

COLOR FIGURES (All articles)

Proceedings of the American Thoracic Society 2005 2: 499-516. [Full Text]  

This article has been cited by other articles:

				C. R. Divgi Molecular Imaging of Pulmonary Cancer and Inflammation Proceedings of the ATS, August 15, 2009; 6(5): 464 - 468. [Abstract] [Full Text] [PDF]

				D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens Application of PET/CT in the Development of Novel Anticancer Drugs Oncologist, January 1, 2008; 13(1): 25 - 38. [Abstract] [Full Text] [PDF]

				Y. Chen, M. A. De Marco, I. Graziani, A. F. Gazdar, P. R. Strack, L. Miele, and M. Bocchetta Oxygen Concentration Determines the Biological Effects of NOTCH-1 Signaling in Adenocarcinoma of the Lung Cancer Res., September 1, 2007; 67(17): 7954 - 7959. [Abstract] [Full Text] [PDF]

				M. B. Dolovich and D. P. Schuster Positron Emission Tomography and Computed Tomography versus Positron Emission Tomography Computed Tomography: Tools for Imaging the Lung Proceedings of the ATS, August 1, 2007; 4(4): 328 - 333. [Abstract] [Full Text] [PDF]